Cannell & Spears’s Bristol-Myers Squibb BMY Stock Holding History

Cannell & Spears’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.7M	Sell	242,592 -8,938	-4%	-$521K	0.29%	83
2025 Q4	$13.6M	Sell	251,530 -1,384	-0.5%	-$66.6K	0.25%	87
2025 Q3	$11.4M	Sell	252,914 -18,177	-7%	-$849K	0.22%	96
2025 Q2	$12.5M	Sell	271,091 -778	-0.3%	-$38.2K	0.25%	91
2025 Q1	$16.6M	Buy	271,869 +342	+0.1%	+$19.9K	0.36%	80
2024 Q4	$15.4M	Sell	271,527 -1,855	-0.7%	-$104K	0.32%	81
2024 Q3	$14.1M	Buy	273,382 +2,698	+1%	+$127K	0.28%	85
2024 Q2	$11.2M	Sell	270,684 -19,486	-7%	-$872K	0.23%	87
2024 Q1	$15.7M	Buy	290,170 +277,340	+2,162%	+$14.1M	0.33%	82
2023 Q4	$658K	Sell	12,830 -344	-3%	-$18.1K	0.05%	120
2023 Q3	$765K	Hold	13,174	–	–	0.07%	104
2023 Q2	$842K	Hold	13,174	–	–	0.07%	104
2023 Q1	$913K	Buy	13,174 +344	+3%	+$24.3K	0.08%	98
2022 Q4	$923K	Buy	12,830 +250	+2%	+$18.9K	0.09%	94
2022 Q3	$894K	Sell	12,580 -68	-0.5%	-$4.93K	0.09%	92
2022 Q2	$974K	Sell	12,648 -285	-2%	-$21.7K	0.09%	94
2022 Q1	$944K	Sell	12,933 -200	-2%	-$13.4K	0.07%	108
2021 Q4	$819K	Buy	13,133 +285	+2%	+$16.7K	0.06%	113
2021 Q3	$760K	Hold	12,848	–	–	0.05%	114
2021 Q2	$859K	Buy	12,848 +3,000	+30%	+$196K	0.06%	107
2021 Q1	$622K	Sell	9,848 -155	-2%	-$9.64K	0.05%	123
2020 Q4	$620K	Hold	10,003	–	–	0.05%	114
2020 Q3	$603K	Hold	10,003	–	–	0.06%	114
2020 Q2	$588K	Sell	10,003 -254	-2%	-$15.2K	0.06%	108
2020 Q1	$572K	Sell	10,257 -1,208	-11%	-$73.8K	0.07%	100
2019 Q4	$736K	Buy	11,465 +1,825	+19%	+$105K	0.08%	81
2019 Q3	$489K	Hold	9,640	–	–	0.06%	103
2019 Q2	$437K	Buy	9,640 +300	+3%	+$14K	0.05%	110
2019 Q1	$446K	Hold	9,340	–	–	0.06%	103
2018 Q4	$485K	Hold	9,340	–	–	0.07%	95
2018 Q3	$580K	Hold	9,340	–	–	0.07%	94
2018 Q2	$517K	Sell	9,340 -7,507	-45%	-$405K	0.07%	98
2018 Q1	$1.07M	Sell	16,847 -3,483	-17%	-$224K	0.14%	62
2017 Q4	$1.25M	Buy	20,330 +6,000	+42%	+$375K	0.15%	54
2017 Q3	$913K	Hold	14,330	–	–	0.11%	63
2017 Q2	$798K	Buy	14,330 +10,600	+284%	+$577K	0.1%	61
2017 Q1	$203K	Hold	3,730	–	–	0.03%	127
2016 Q4	$218K	Sell	3,730 -9,465	-72%	-$517K	0.03%	123
2016 Q3	$711K	Buy	13,195 +9,432	+251%	+$606K	0.09%	64
2016 Q2	$277K	Hold	3,763	–	–	0.04%	98
2016 Q1	$240K	Sell	3,763 -2,650	-41%	-$167K	0.03%	112
2015 Q4	$441K	Sell	6,413 -350	-5%	-$23.1K	0.05%	88
2015 Q3	$400K	Buy	6,763 +1,000	+17%	+$63.4K	0.05%	94
2015 Q2	$383K	Sell	5,763 -1,800	-24%	-$119K	0.04%	104
2015 Q1	$488K	Hold	7,563	–	–	0.06%	94
2014 Q4	$446K	Hold	7,563	–	–	0.05%	101
2014 Q3	$387K	Sell	7,563 -6,481	-46%	-$324K	0.05%	103
2014 Q2	$681K	Buy	14,044 +7,944	+130%	+$391K	0.08%	77
2014 Q1	$317K	Hold	6,100	–	–	0.04%	93
2013 Q4	$324K	Hold	6,100	–	–	0.04%	93
2013 Q3	$282K	Buy	+6,100	New	+$268K	0.04%	100

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cannell & Spears's BMY Position: Q1 2026 in Review

Cannell & Spears reduced its Bristol-Myers Squibb (BMY) stake by 3.6% in Q1 2026, selling an estimated $521K and leaving 242,592 shares worth $14.7M. The position accounts for 0.29% of the portfolio, ranked #83.

Cannell & Spears first reported a position in BMY in Q3 2013 and has held it in 51 quarters since. The position peaked at $16.6M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Cannell & Spears held 242,592 shares of Bristol-Myers Squibb worth $14.7M as of Q1 2026.
Cannell & Spears sold 8,938 Bristol-Myers Squibb shares in Q1 2026, an estimated $521K.
Bristol-Myers Squibb made up 0.29% of Cannell & Spears's portfolio in Q1 2026, its #83 holding.
Cannell & Spears first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 51 quarters since.
Cannell & Spears's Bristol-Myers Squibb position peaked at $16.6M in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.